RecruitingNot ApplicableNCT07337772

Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty

Prospective Randomized Controlled Trial Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

120 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Adrenal Cortex Hormones

Summary

This study aims to compare the efficacy of different doses of glucocorticoids in local infiltration analgesia (LIA) during total knee arthroplasty (TKA) through a prospective single-center randomized controlled trial, and to explore the safety and feasibility of high-dose glucocorticoids. Through this research, the investigators hope to provide an optimized solution for post-TKA pain management, improve patients' postoperative recovery and quality of life, and offer scientific evidence for pain management following TKA.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria4

Male or female participants aged 18 years or older;
Undergoing primary unilateral total knee arthroplasty (TKA)for unilateral knee osteoarthritis(OA)at ourhospital;
Preoperative American Society of Anesthesiologists(ASA)physical status classification of 1-3;
Ability to provide informed consent and sign a written informed consent form.

Exclusion Criteria7

Previous surgery on the operative knee or a history of infection in the operative knee;
Non-osteoarthritis conditions (including rheumatoid arthritis, traumatic arthritis, septic arthritis, and hemophilic arthritis);
Severe osteoarthritis (including flexion contracture \>30° or varus/valgus deformity \>30°);
Allergy to the relevant study drugs;
Presence of neuromuscular dysfunction in the ipsilateral limb;
Dependence on anesthetic drugs (defined as weekly use of opioids exceeding 100 mg morphine equivalents or local anesthetics for preoperative pain control for more than 3 months);
Poor systemic condition, including but not limited to: glycated hemoglobin (HbA1c) level \>12%; blood pressure \>170/110 mmHg (1 mmHg = 0.133 kPa); history of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure, or any acute coronary event within 6 months; dialysis or renal transplantation; pregnancy or lactation.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLIA with different doses of Diprospan

LIA with different doses of Diprospan

Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07337772